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Abstract
Background: Aortic valve stenosis is one of the most common heart diseases in older patients. Nowadays, surgical
aortic valve replacement is the ‘gold standard’ treatment for this pathology and the most implanted prostheses are
biological ones. The three most implanted bovine bioprostheses are the Trifecta valve (St. Jude Medical,
Minneapolis, MN, USA), the Mitroflow valve (Sorin Group, Saluggia, Italy), and the Carpentier-Edwards Magna Ease
valve (Edwards Lifesciences, Irvine, CA, USA). We propose a randomized trial to objectively assess the hemodynamic
performances of these bioprostheses.
Methods and design: First, we will measure the aortic annulus diameter using CT-scan, echocardiography and by
direct sizing in the operating room after native aortic valve resection. The accuracy of information, in terms of size
and spatial dimensions of each bioprosthesis provided by manufacturers, will be checked. Their hemodynamic per-
formances will be assessed postoperatively at the seventh day and the sixth month after surgery.
Discussion: This prospective controlled randomized trial aims to verify and compare the hemodynamic
performances and the sizing of these three bioprostheses. The data obtained may help surgeons to choose the
best suitable bioprosthesis according to each patient’s morphological characteristics.
Trial registration: ClinicalTrials.gov Identifier: NCT01522352
Keywords: Stented pericardial aortic valves, Pericardial aortic valves, Hemodynamic performance
Background
A critical aspect of aortic valve replacement is to achieve
an optimal matching between the patient’s morphology
and the implanted valve prosthesis. Specifically, the im-
planted prosthesis should not impair left ventricle ejection
and this is even more crucial in cases where there is a
small aortic annulus.
Pericardial bioprostheses have good hemodynamic
performance because of their central opening and the
flexibility of their leaflets. We already know that the
durability of these pericardial bioprostheses is about 10
to 15 years [1,2].
At present, porcine bioprostheses are less well-
performing than bovine pericardial ones [3] and among
these, we focused on three bioprostheses offering high
hemodynamic performance, especially for small aortic
valves.
Since March 2010, a new pericardial aortic valve
bioprosthesis (Trifecta valve, St. Jude Medical, Minneapolis,
MN, USA) has been approved by the Food and Drugs
Administration (FDA approval: St Jude Medical Trifecta
Valve - P100029) and has recently received the CE mark.
However, its hemodynamic characteristics still need to be
compared with other bioprostheses already available on
the market. Another bioprosthesis chosen for this trial is
the Mitroflow valve (Sorin Group, Saluggia, Italy) [4]: it
received the CE mark in July 2011 and it is characterized
by an innovative phospholipid reduction treatment (PRT)
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expressively conceived to reduce the calcification process
and, as a consequence, to improve its durability.
The third bioprosthesis is the Carpentier-Edwards
Magna Ease valve (Edwards Lifesciences, Irvine, CA, USA)
which has been designed by developing the renowned and
highly performing Carpentier-Edwards PERIMOUNT
valves. It allows easier implantation and its pericardial
tissue is additionally treated to prevent calcification. This
bioprosthesis received the CE mark in 2007 and FDA ap-
proval in 2009.
Objectives of the Trivalve study
Each aortic valve has its own hemodynamic characteris-
tics related to its geometry and each patient has their
own morphology (weight, size, anatomy of aortic valve),
as well as different physiological and pathophysiological
conditions (ejection fraction, size and degree of calcifi-
cation of the aortic annulus, degree of left ventricular
hypertrophy and so on). Consequently, the choice of
valve prosthesis and the surgical implantation technique
are the only two directly adjustable variables; nonethe-
less, current literature does not provide clear differences
among available bioprostheses.
The main objective of this study is to measure the
hemodynamic performance of the three aortic bioprosth-
eses: the Trifecta valve (St. Jude Medical, Minneapolis,
MN, USA), the Mitroflow valve (Sorin Group, Saluggia,
Italy), and the Magna Ease valve (Edwards Lifesciences,
Irvine, CA, USA) Table 1.
Secondary end points will focus on 1) comparison
between the effective aortic orifice area measured by
computerized tomography (CT)-scan and echocardiog-
raphy and the intraoperative measurement performed by
a flat-head candle; 2) comparison between the diameter
of the aortic orifice measured by a flat-head candle and
the size of the implanted bioprosthesis provided by the
manufacturer; 3) testing the accuracy of information
provided by the manufacturers about bioprosthesis
diameters.
Methods and design
The Trivalve trial is a single-center, prospective, random-
ized trial. It will evaluate the short-term (six month)
hemodynamic performance of three pericardial bioprosth-
eses: the Trifecta valve (St. Jude Medical, Minneapolis,
MN, USA), the Mitroflow valve (Sorin Group, Saluggia,
Italy), and the Carpentier-Edwards Magna Ease valve
(Edwards Lifesciences, Irvine, CA, USA), Figure 1.
ClinicalTrials.gov Identifier: NCT01522352.
Patient’s enrollment and randomization
All patients scheduled for surgical aortic valve replace-
ment by bioprosthesis will be screened according to
inclusion and exclusion criteria (Table 2).
Patients who have given their signed informed consent
to participate in this clinical trial will undergo, preopera-
tively, a CT-scan and a transthoracic echocardiogram to
measure the aortic annulus. Included patients will be
randomly allocated to receive one of the three biopro-
stheses, in a 1:1:1 ratio. When a patient is considered
eligible and informed consent has been obtained,
randomization will be performed automatically (using
STATA software (StataCorp, College Station, TX, USA)
before surgery by an independent biostatistician. No
stratification will be done. The selected bioprosthesis
will be implanted.
Preoperative measurements
Preoperative CT-scan measured data, echocardiography
and surgical measurements are shown in Table 3.
Surgery
During surgery, the aortic valve of the patient will be
completely removed and the aortic annulus measured
using a flat-head candle. This universal candle has been
specifically designed to give a single objective value of
the internal diameter of the aortic annulus. The Hegar
dilators will not be used as its round shape and arched
aerodynamics overestimate the size of the annulus by
applying opening force to its passage (Figure 2). All
measurements, early postoperative complications and
reoperations for bleeding will be recorded in the opera-
tive report and in the case-report form.
Postoperative endpoints
All preoperative echocardiography collected measures
will be reassessed at day seven and month six after
surgery in addition to maximal and mean transvalvular
gradients (mmHg). ICU, total hospital stay and any other
postoperative complications will be recorded in the post-
operative report and in the case-report form.
Table 1 Bioprosthesis characteristics
Bioprosthesis type Manufacturer Valve diameters (mm)
Trifecta St. Jude Medical, Minneapolis, USA 19 to 29
Mitroflow Sorin Group, Saluggia, Italy 19 to 29
Carpentier-Edwards Magna Ease Edwards Lifesciences, Irvine, USA 19 to 29
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The primary endpoint is the mean transvalvular gradi-
ent (mmHg) six months after surgery. All secondary
endpoints are indicated in Table 4.
Statistical considerations
Sample size estimation
The estimation of the number of patients required was
considered by using previous data provided by the manu-
facturers on patients who had cardiovascular surgery
which showed the mean postoperative gradients (mmHg)
for the three studied types of valve (data not published). A
minimum difference (δ) of 4 mmHg could be expected
between the three types of valve for the most relevant
diameters (21 and 23 mm). As the information concerning
statistical variability was not provided in this document,
the standard deviation (σ) was estimated on the basis of
data from 103 patients observed in our center (84 with
the Edwards Ease prosthesis, 19 with a Mitroflow dia-
meter of 21 or 23 mm): σ = 5.8. Thus, for a type 1 error
α = 0.05 (two-sided), a 90 %-power, δ = 4 and σ = 5.8, 44
subjects per group are needed. Taking into account
multiple comparisons between the three randomized
groups, 55 patients per group will be included (165 patients
in total).
Statistical analyses
All analyses will be performed using STATA v11
(StataCorp, College Station, TX, USA). A two-tailed
P-value of 0.05 will be considered statistically significant.
All analyses will be performed on an intention-to-treat
(ITT) basis. The number of included patients and the
rate of inclusions will be presented over time for each
(D-45 to D-7) PREOPERATIVE CONSULTATION
- Patients' information
- Previous history
- Clinical tests
- Aortic CT with measurement of the aortic ring
(D-2 to D-1) PREOPERATIVELY
- Collect the patient’s consent
- Echography:
o Measurement of the aortic-valve ring
o Hemodynamic parameters
o Measurement of preoperative 
transvalvular gradient 
(D0) SURGERY
- Randomization of the bioprosthesis to be 
implanted 
- Surgical measurement of the aortic ring
(D7 to D10) END OF HOSPITALIZATION
- Clinical tests
- Post-operative echography
o Hemodynamic parameters
o Measurement of postoperative 
transvalvular gradient
- Record any complications
- Time hospitalized in the ICU 
- Total time of postoperative stay
- Undesirable serious events
(6 months ± 15D) POSTOPERATIVE VISIT
- Clinical tests
- Postoperative echography:
o Hemodynamic parameters
o Measurement of postoperative 
transvalvular gradient
- Undesirable serious events
Figure 1 Study’s flowchart.
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group. The patients will be described and compared
between groups at baseline according to the following
variables: compliance with eligibility criteria, epidemio-
logical features, clinical features (including echocardio-
graphic) and biological characteristics. The comparison
concerning the postoperative means of the transvalvular
gradients (measured by echocardiography at six months
post surgery) between the three groups will be evaluated
using ANOVA followed by the Tukey-Kramer post hoc
test, or the Kruskal-Wallis nonparametric test if condi-
tions of ANOVA are not met (homoscedasticity studied
by Bartlett’s test and normality verify by Shapiro-Wilk)
followed by Dunn’s test as appropriate. Comparisons
between the groups will be realized systematically 1)
without adjustment and 2) when appropriate, after
adjustment (by multivariate linear regression model) on
factors whose distribution could be unbalanced between
the arms despite randomization. Quantitative secondary
endpoints (for example hemodynamic data, CT-scan, in-
hospital stay) will be analyzed as described above.
Categorical parameters (that is, proportion of reoperations)
will be compared between the groups using the chi-
squared test or Fisher’s exact test, when necessary. To as-
sess the relationships between the quantitative parameters
(comparison between aortic orifice measurements by
echocardiography, CT-scans, intraoperative measurement
using the flat- candle versus the size of implanted valve
prosthesis given by the manufacturer), the correlation
coefficients (Pearson or Spearman), the Lin concordance
coefficient and the intra-class coefficient (ICC) will be
calculated. Later on, an ANCOVA could be proposed to
consider group effect. The intra-group comparisons re-
lated to the quantitative criteria (hemodynamic data by
echocardiography on preoperative period and at six
months) will be made using paired the ANOVA or
Wilcoxon test. Finally, to avoid bias induced by the
presence of missing data, particularly with regards to the
mean postoperative transvalvular gradient at six months
(lost at follow-up or deaths), the primary analysis (ITT
Table 2 Inclusion and exclusion criteria
Inclusion criteria Isolated aortic valve replacement or associated
with myocardial revascularization and/or tricuspid
valve repair
Age (> 18 years and < 85 years)
Exclusion criteria Emergency surgery
Surgery other than full sternotomy
Heart transplantation
Any procedure involving the aorta (such as Bentall
procedure, surgery for dissection, and so on)
Redo surgery
Active infective endocarditis
Associated mitral valve surgery
Heart failure (ejection fraction < 40%) or
preoperative cardiogenic shock
Systolic pulmonary arterial pressure > 60 mmHg
Patient’s protocol refusal
Pregnancy
Mentally handicapped patients, pre-existing
psychiatric disease or addiction
Advanced respiratory failure (forced expiratory
volume in 1 second or vital capacity below
50% of the predicted)
Severe renal failure
History of allergy or intolerance to iodinated
contrast infusion
Patients living more than 100 km away from
the investigation center
Table 3 CT-scan, echocardiographic and surgical
measurements
Preoperative
data
Operative
data
Day
7 data
Month
6 data
CT-scan
Native aortic annulus (mm) X
Ascending aorta
diameter (mm)
X
Echocardiography
LVTS (mm) X X X
LVTD (mm) X X X
LVPWT (mm) X X X
IVST (mm) X X X
LVSF (%) X X X
LVEF (%) X X X
Pulmonary arterial pressure X X X
Cardiac output (L/min-1) X X X
Cardiac index (L/min-1/m-2) X X X
Mean transvalvular
gradient (mmHg)
X X X
Maximal transvalvular
gradient (mmHg)
X X X
Aortic orifice area (m2) X X X
Aortic regurgitation
degree (0–4)
X X X
Paravalvular leak X X
Surgery
Internal aortic annulus
diameter (mm)
X
Estimated valve
diameter (mm)
X
Implanted valve
diameter (mm)
X
IVST: inter ventricular septum thickness, LVEF: left ventricular ejection fraction,
LVPWT: left ventricle posterior wall thickness, LVSF: left ventricular shortening
fraction, LVTD: left ventricle tele diastolic diameter, LVTS: left ventricle tele
systolic diameter.
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with imputation data determined according to quantity
and type of missing data) will be completed on a second
time by a per-protocol analysis.
Expected adverse events
These three prosthetic valves are made of three layers of
fixed bovine pericardium assembled on a support (stent).
They are then fixed in a glutaraldehyde solution and
conditioned in a sterile manner. A correctly sized and
implanted valve leads to very few complications. They
have an average lifespan of > 10 years when implanted in
patients aged > 65 years [1,2]. The expected adverse
events of these bioprostheses are those of usual heart valve
replacement surgery on cardiopulmonary bypass and
mortality can be predicted by Euroscore 2 [5], which is
systematically calculated for all our patients. Postoperative
adverse events will be evaluated according to the Clavien-
Dindo classification for surgical complications [6].
Funding
Edwards Lifesciences (Irvine, CA, USA), St. Jude Medical
(Minneapolis, MN, USA), and Sorin Group (Saluggia,
Italy) gave a contribution of €5,000 each and the Hospital
Clinical Research Program (PHRC) of the French Ministry
of Health contributed an amount of €15,000 for the
realization of this study.
The status of this trial
This trial has been actively recruiting patients since
March 2012. The French Committee on Human Research
(CPP Sud-Est VI) consented to this trial on 17 January
2012. Patients give their informed consent before being
enrolled in this study. Agreement from the French
Competent Authority (ANSM) was obtained on 23 June
23 2011. The completion date for this study is estimated
as December 2014. The ClinicalTrials.gov identifier is
NCT01522352.
Discussion
Several studies have emphasized the importance of valve
prosthesis hemodynamic performance [7,8], but none
has taken into account more than one or two bioprosth-
eses at a time [9,10]. Thus, we strongly believe that a
randomized trial, with no direct conflicts of interest with
industry, is mandatory to compare the three bioprosth-
eses most commonly implanted in France and all around
the world.
Our secondary objective is to compare the reliability
of preoperative CT-scan and echocardiography used to
assess the size of the aortic annulus in comparison to
the surgical measurement. Both techniques (CT-scans and
echocardiography) are already successfully used to predict
the correct size of the aortic annulus before trans-catheter
valve implantation procedures [11]. Another secondary
Figure 2 Importance of the use of flat-head candles to measure
the aortic ring (bottom of the picture) compared to Hegar
dilators.
Table 4 Primary and secondary endpoints
Primary endpoint Mean transvalvular gradient (mmHg), six months
after surgery
Secondary endpoints Effective aortic orifice diameter measured by
CT-scan and echocardiography compared with
the surgical data (mm)
Mean transvalvular gradient (mmHg), at day
seven after surgery
Aortic bioprosthesis orifice area (m2), six months
after surgery
Diameter of the aortic orifice measured by a
flat-head candle compared with the size of the
implanted bioprosthesis (mm)
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objective, once we have assessed the surgical diameter of
the aortic annulus intraoperatively, is to verify the reliabil-
ity of the prosthesis size provided by the manufacturer.
This last point is interesting as it aims to clarify an issue
often debated by surgeons who complain to manufac-
turers that they over- or underestimate valve sizes. Precise
information on the size of the implanted bioprosthesis
compared to the real dimensions of the aortic annulus will
guide cardiac surgeons to choose between these three
bioprostheses according to the patient’s morphological
characteristics.
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